# Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects

> **NCT05905484** · PHASE1 · COMPLETED · sponsor: **Atea Pharmaceuticals, Inc.** · enrollment: 35 (actual)

## Conditions studied

- Healthy Volunteer Study

## Interventions

- **DRUG:** Bemnifosbuvir (BEM)
- **DRUG:** Placebo
- **DRUG:** Moxifloxacin

## Key facts

- **NCT ID:** NCT05905484
- **Lead sponsor:** Atea Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-25
- **Primary completion:** 2023-05-31
- **Final completion:** 2023-05-31
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2023-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05905484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05905484, "Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05905484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*